Overview
Bevespi Aerosphere is a prescription drug approved by the Food and Drug Administration (FDA) as long-term maintenance treatment for airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere is a combination drug composed of Glycopyrrolate and Formoterol fumarate.

Glycopyrrolate is an anticholinergic. Formoterol fumarate is a long-acting beta2-adrenergic agonist (LABA). Both drugs are bronchodilators. Both drugs are believed to work by relaxing and dilating the airways, making it easier to breathe.

How do I take it?
Bevespi Aerosphere is taken twice daily.

Bevespi Aerosphere comes as an inhaler.

Side effects... read more

MyCOPDTeam is a free social network that makes it easy to find others like you and gain insights from others living with COPD.
Sign up Log in